S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
TSE:HLS

HLS Therapeutics Inc. (HLS.TO) Stock Forecast, Price & News

C$18.36
+0.14 (+0.77 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
C$17.90
Now: C$18.36
C$18.81
50-Day Range
C$16.37
MA: C$17.49
C$19.00
52-Week Range
C$13.35
Now: C$18.36
C$21.60
Volume14,067 shs
Average Volume35,772 shs
Market CapitalizationC$582.82 million
P/E RatioN/A
Dividend Yield1.10%
BetaN/A
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and Barbados. Its lead product is Clozaril, an atypical antipsychotic used in the treatment of schizophrenia. The company also holds the U.S. marketing rights of Absorica, a commercial stage dermatology product. HLS Therapeutics Inc. has a license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. The company was founded in 2018 and is headquartered in Toronto, Canada.

Headlines

HLS Therapeutics Establishes Automatic Share Purchase Plan
November 19, 2020 |  finance.yahoo.com
When Will HLS Therapeutics Inc. (TSE:HLS) Breakeven?
August 10, 2020 |  finance.yahoo.com
HLS Therapeutics misses on revenue
August 6, 2020 |  seekingalpha.com
HLS Therapeutics Announces Q2 2020 Financial Results
August 6, 2020 |  finance.yahoo.com
HLS Therapeutics Confirms Annual Shareholders' Meeting
June 10, 2020 |  finance.yahoo.com
HLS Therapeutics beats on revenue
May 7, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone647-495-9000
Employees64
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$53.56 million
Cash FlowC$0.66 per share
Book ValueC$5.32 per share

Profitability

Miscellaneous

Market CapC$582.82 million
Next Earnings Date3/18/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.26 out of 5 stars

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
C$18.36
+0.14 (+0.77 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HLS News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











HLS Therapeutics Inc. (HLS.TO) (TSE:HLS) Frequently Asked Questions

Is HLS Therapeutics Inc. (HLS.TO) a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics Inc. (HLS.TO) in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HLS Therapeutics Inc. (HLS.TO) stock.
View analyst ratings for HLS Therapeutics Inc. (HLS.TO)
or view top-rated stocks.

What stocks does MarketBeat like better than HLS Therapeutics Inc. (HLS.TO)?

Wall Street analysts have given HLS Therapeutics Inc. (HLS.TO) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but HLS Therapeutics Inc. (HLS.TO) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is HLS Therapeutics Inc. (HLS.TO)'s next earnings date?

HLS Therapeutics Inc. (HLS.TO) is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for HLS Therapeutics Inc. (HLS.TO)
.

How has HLS Therapeutics Inc. (HLS.TO)'s stock been impacted by COVID-19?

HLS Therapeutics Inc. (HLS.TO)'s stock was trading at C$18.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HLS stock has decreased by 2.1% and is now trading at C$18.36.
View which stocks have been most impacted by COVID-19
.

How often does HLS Therapeutics Inc. (HLS.TO) pay dividends? What is the dividend yield for HLS Therapeutics Inc. (HLS.TO)?

HLS Therapeutics Inc. (HLS.TO) announced a quarterly dividend on Wednesday, November 4th. Stockholders of record on Friday, January 29th will be given a dividend of 0.05 per share on Monday, March 15th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 1.09%. The ex-dividend date is Thursday, January 28th.
View HLS Therapeutics Inc. (HLS.TO)'s dividend history
.

Is HLS Therapeutics Inc. (HLS.TO) a good dividend stock?

HLS Therapeutics Inc. (HLS.TO) pays an annual dividend of C$0.15 per share and currently has a dividend yield of 1.10%.
View HLS Therapeutics Inc. (HLS.TO)'s dividend history.

What price target have analysts set for HLS?

2 brokers have issued 1 year price targets for HLS Therapeutics Inc. (HLS.TO)'s stock. Their forecasts range from C$27.00 to C$27.00. On average, they expect HLS Therapeutics Inc. (HLS.TO)'s share price to reach C$27.00 in the next year. This suggests a possible upside of 47.1% from the stock's current price.
View analysts' price targets for HLS Therapeutics Inc. (HLS.TO)
or view top-rated stocks among Wall Street analysts.

Who are HLS Therapeutics Inc. (HLS.TO)'s key executives?

HLS Therapeutics Inc. (HLS.TO)'s management team includes the following people:
  • Mr. William M. Wells M.B.A., B.A., MBA, Co-Founder & Exec. Chairman (Age 60, Pay $609.94k)
  • Mr. Gilbert Godin, Co-Founder, Pres, CEO & Director (Age 62, Pay $818.28k)
  • Mr. Gregory David Gubitz L.L.B., B.A., LL.B, Co-Founder & Director (Age 64, Pay $819.04k)
  • Mr. Tim Hendrickson M.B.A., Chief Financial Officer (Age 49, Pay $350.69k)
  • Mr. Sanjiv Sharma, Chief Commercial Officer (Age 65, Pay $469.04k)
  • Mr. Ryan C. Lennox, Gen. Counsel & Corp. Sec. (Age 40)
  • Dr. Hemanth Jacob Varghese, Head of Corp. Strategy & Bus. Devel. (Age 45)

Who are some of HLS Therapeutics Inc. (HLS.TO)'s key competitors?

What other stocks do shareholders of HLS Therapeutics Inc. (HLS.TO) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics Inc. (HLS.TO) investors own include Cargojet Inc. (CJT.TO) (CJT), Fairfax Financial (FFH), Fortis (FTS), Aurora Cannabis (ACB), Aphria (APHA), Alimentation Couche-Tard (ATD.B), BlackBerry (BB), BCE (BCE), Bank of Montreal (BMO.TO) (BMO) and The Bank of Nova Scotia (BNS.TO) (BNS).

What is HLS Therapeutics Inc. (HLS.TO)'s stock symbol?

HLS Therapeutics Inc. (HLS.TO) trades on the Toronto Stock Exchange (TSX) under the ticker symbol "HLS."

How do I buy shares of HLS Therapeutics Inc. (HLS.TO)?

Shares of HLS and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is HLS Therapeutics Inc. (HLS.TO)'s stock price today?

One share of HLS stock can currently be purchased for approximately C$18.36.

How much money does HLS Therapeutics Inc. (HLS.TO) make?

HLS Therapeutics Inc. (HLS.TO) has a market capitalization of C$582.82 million and generates C$53.56 million in revenue each year.

How many employees does HLS Therapeutics Inc. (HLS.TO) have?

HLS Therapeutics Inc. (HLS.TO) employs 64 workers across the globe.

What is HLS Therapeutics Inc. (HLS.TO)'s official website?

The official website for HLS Therapeutics Inc. (HLS.TO) is www.hlstherapeutics.com.

How can I contact HLS Therapeutics Inc. (HLS.TO)?

The company can be reached via phone at 647-495-9000.


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.